[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"analgesia-assessment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:analgesia-assessment":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,57,87,114,145,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054207","the-analgesic-efficacy-of-dexmedetomidine-versus-fentanyl-as-an-adjuvant-to-bupivacaine-in-ultrasound-guided-peripheral-nerve-blocks-as-a-solo-anesthetic-technique-in-high-risk-patients-undergoing-unilateral-above-knee-amputation--100054207",false,"NCT07640516","The Analgesic Efficacy of Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Ultrasound Guided Peripheral Nerve Blocks as a Solo Anesthetic Technique in High Risk Patients Undergoing Unilateral Above Knee Amputation .","The Analgesic Efficacy of Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Ultrasound Guided Peripheral Nerve Blocks as a Solo Anesthetic Technique in High Risk Patients Undergoing Unilateral Above Knee Amputation : A Randomized Double Blinded Study","Inclusion Criteria:\n\n* \\- Age ≥18 years\n* Both sexes\n* ASA III-IV\n* Documented cardiac disease (e.g., EF \\\u003C 40%, NYHA II or higher)\n* Documented pulmonary disease (e.g., COPD with FEV1 \\\u003C 60%)\n* Scheduled for above-knee amputations\n\nExclusion Criteria:\n\n* Neurological or intellectual disability\n* Drug abuse\n* Allergy to study drugs\n* Pregnancy\n* Contraindications to regional anesthesia (e.g., coagulopathy, local infection)\n* Significant renal or hepatic impairment( plts \\\u003C75000 or INR \\>1.5)\n* Current anticoagulant therapy\n* severe haemodynamically unstability at the time of block performance, defined as map \\> 65 mmhg but achieved by high-dose vasopressors (e.g., norepinephrine ≥ 0.1 mcg\u002Fkg\u002Fmin) after fluid ressuscitation .","ALL","18 Years",{"count":19,"type":20},64,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to compare the analgesic efficacy and safety of dexmedetomidine versus fentanyl as adjuvants to bupivacaine in ultrasound-guided combined supra-inguinal fascia iliaca and proximal sciatic nerve blocks used as a solo anesthetic technique in high-risk patients undergoing unilateral above knee amputation.",[26,27,28],"Analgesia Assessment","Above Knee Amputation","Fentanyl vs Dexmedetomidine",[30],"dexmedetomidine vs fentanyl PNBs AKA","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":20},"2026-07-01",{"date":39,"type":20},"2027-03-01",{"name":41,"class":42},"Kasr El Aini Hospital","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":47,"briefSummary":24,"conditions":48,"keywords":49,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":56,"locationsCount":43},"100643114",{"count":19,"type":20},[23],[26,27,28],[30],"NOT_YET_RECRUITING","2026-06-06",{"date":53,"type":35},"2026-06-10",{"date":37,"type":20},{"date":39,"type":20},{"name":41,"class":42},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":76,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":43},"100635814","effect-of-opioid-free-vs-opioid-based-anesthesia-on-postoperative-pain-and-emergence-agitation-in-children-undergoing-cleft-surgery-100635814","NCT07557576","Effect of Opioid-Free vs Opioid-Based Anesthesia on Postoperative Pain and Emergence Agitation in Children Undergoing Cleft Surgery","Comparison of Impact of Opioid and Non-Opioid Anesthesia on Pain and Agitation Levels in Children After Cleft Lip and Palate Surgery","Inclusion Criteria:\n\n* ASA physical status I-II\n* Body weight \\>5 kg\n* Age ≥3 months for cleft lip repair and ≥9 months for cleft palate repair\n* Hemoglobin \\>100 g\u002FL\n\nExclusion Criteria:\n\n* ASA physical status III-IV\n* Body weight \\\u003C5 kg\n* Age \\\u003C3 months for cleft lip repair or \\\u003C9 months for cleft palate repair\n* Hemoglobin \\\u003C100 g\u002FL\n* Acute illness\n* Respiratory infection or vaccination within 2 weeks prior to surgery\n* Requirement for perioperative intensive care","3 Months","7 Years",{"count":67,"type":20},90,[23],"Orofacial clefts are among the most common congenital malformations, affecting approximately 1 in 700-1500 live births worldwide. They are associated not only with aesthetic concerns but also with functional impairments in feeding, speech, hearing, and dentition, and may be accompanied by other systemic malformations, often requiring multiple surgical procedures and long-term multidisciplinary care. Although cognitive development is preserved, the psychosocial impact on both children and families can be significant.\n\nAnesthesia in children with clefts presents specific challenges. Airway management is often more difficult due to anatomical variations, particularly in syndromic patients and those under 1 year of age. Immature organ systems affect drug metabolism, requiring careful dose adjustment. Preoperative anxiety and stress responses are common and may contribute to complications such as laryngospasm and bronchospasm. In the postoperative period, emergence agitation (EA) and emergence delirium (ED) are frequent, with reported incidence up to 80%. These conditions are characterized by restlessness, inconsolability, and disorientation, and may result in self-injury or disruption of surgical repairs.\n\nDifferentiating agitation from pain is challenging in young children due to limited communication abilities. Validated observational tools such as CHIPPS, PAEDS, and Cravero scales are used for routine clinical assessment of pain and EA\u002FED, although their subjective nature may limit accuracy. Therefore, evaluation of the perioperative serum cortisol, alpha-amylase, and neuropeptide Y levels will be used. These biomarkers reflect activation of the physiological stress response and indirectly indicate the presence and intensity of pain.\n\nPain management requires a multimodal approach. While opioids remain standard, their use is associated with adverse effects such as respiratory depression, nausea, vomiting, and delayed recovery. Consequently, opioid-free (OF) strategies using different anesthetics, including ketamine and dexmedetomidine have gained attention.\n\nThis prospective randomized clinical trial will compare opioid-based anesthesia with an opioid-free protocol in children undergoing cleft surgery. A total of 90 patients age of 3 months-7 years will be randomized in a 1:1 ratio. The opioid group will receive fentanyl, while the OF group will receive ketamine and dexmedetomidine; both groups will receive propofol, vecuronium, sevoflurane, and nitrous oxide.\n\nPrimary outcomes are postoperative pain (CHIPPS) and emergence agitation (PAEDS, Cravero). Pain will be assessed at 5 min, 15 min, 1, 2, 12, and 24 h after extubation, whereas emergence agitation will be evaluated at 5 min, 15 min, 1 h, and 2 h post-extubation. While these scales are routinely used in clinical practice, their subjective nature necessitates additional objective assessment. Therefore, secondary outcomes include evaluation of perioperative stress markers (cortisol, alpha-amylase, neuropeptide Y) and adverse events (nausea, vomiting, pruritus, constipation, respiratory depression, altered consciousness) within 24 h. Procedures will be standardized, with morning surgeries to minimize circadian variations of the biomarkers, performed by the same team. Blood samples will be collected before and after intravenous induction.\n\nPostoperative analgesia will include paracetamol and NSAIDs, with fentanyl as rescue therapy.\n\nThe study hypothesis is that opioid-free anesthesia will provide comparable or superior analgesia, reduce the incidence of emergence agitation, attenuate the stress response, and decrease opioid-related adverse effects, thereby improving overall perioperative safety and recovery in pediatric patients undergoing cleft surgery.\n\nThe particular value of this study lies in the subgroup of children who will undergo at least two surgical procedures within the observation period. In these patients, each child will be exposed to both anesthetic protocols in separate procedures-once according to the randomly assigned regimen and the second time according to the alternative protocol. In this way, each patient serves as their own control, allowing for a more precise comparison of outcomes with a substantial reduction in inter-individual variability. This approach largely eliminates individual differences such as age, body weight, baseline hemodynamic status, individual sensitivity to anesthetics and analgesics, as well as variability in stress response and pain perception. Such a design enhances the internal validity of the study and enables a more reliable interpretation of the results.",[71,72,73,26,74,75],"Cleft Lip Palate","Orofacial Cleft","Agitation, Emergence","Analgesia","Pediatric",[77],"Anesthesia, orofacial clefts, pain control, emergence agitation","2026-04-22",{"date":80,"type":35},"2026-04-29",{"date":82,"type":35},"2024-05-16",{"date":84,"type":20},"2026-09-30",{"name":86,"class":42},"Iva Smiljanić",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100634109","phase-4-bupivacaine-liposome-suspension-administration-to-decreasre-peri-procedural-pain-in-interventional-radiology-ir-procedures-100634109","NCT07535411","Bupivacaine Liposome Suspension Administration to Decreasre Peri-procedural Pain in Interventional Radiology (IR) Procedures","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* chronic pain condition",true,"95 Years",{"count":96,"type":20},10,[98],"PHASE4","This study evaluates the use of liposomal bupivacaine (Exparel), a long-acting local anesthetic, for peri-procedural pain control in patients undergoing interventional radiology (IR) procedures. Effective pain management during and after IR procedures is important for patient comfort, procedural success, and recovery, yet standard local anesthetics (e.g., lidocaine or bupivacaine HCl) provide relatively short durations of analgesia.\n\nLiposomal bupivacaine is an FDA-approved formulation designed to provide extended-release local anesthetic effects over a prolonged period. Its use has been studied in surgical settings, but data in interventional radiology procedures remain limited. This prospective, single-arm quality improvement initiative aims to assess whether incorporation of liposomal bupivacaine into routine procedural care improves patient-reported pain outcomes.\n\nAdult patients undergoing IR procedures will receive liposomal bupivacaine administered by the proceduralist as part of standard care. Pain will be assessed using a structured patient-reported outcome survey at multiple time points, including pre-procedure, during the procedure, 1 hour post-procedure, and within 24 hours post-procedure. The survey also captures use of additional analgesic medications within the first 24 hours.\n\nThe primary outcome is patient-reported pain intensity. Secondary outcomes include post-procedural analgesic utilization. Data will be analyzed descriptively given the exploratory nature and small sample size.\n\nFindings from this project may inform future approaches to pain management in interventional radiology and help determine whether longer-acting local anesthetics provide clinically meaningful improvements in patient experience.",[26],[102,103,104],"Liposomal Bupivicaine","Exparel","Local Anesthesia","2026-04-10",{"date":107,"type":35},"2026-04-17",{"date":109,"type":20},"2026-05",{"date":111,"type":20},"2026-07",{"name":113,"class":42},"Massachusetts General Hospital",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":43},"100627660","comparative-analysis-of-analgesic-approaches-in-the-early-period-after-cabg-100627660","NCT07451522","Comparative Analysis of Analgesic Approaches in the Early Period After CABG","Comparative Characteristics of Analgesia Methods in the Early Postoperative Period After Coronary Artery Bypass Grafting (CABG)","CABG-PAIN","Inclusion Criteria:\n\n* ASA score less then 3, Signed inform consent, Absence of preoperative drugs administration that affects patient's perception of pain, No active infection process, BMI index \\>18,5 kg\\\\m2 and \\\u003C 35 kg\u002Fm2, CABG, Age 18-75 years\n\nExclusion Criteria (the presence of at least one is sufficient):\n\n* Failure to meet the inclusion criteria.\n* High severity according to ASA (class IV or higher), which is associated with a high probability of prolonged mechanical ventilation, hemodynamic instability, and inability to use drugs affecting cardiac output and\u002For total peripheral vascular resistance.\n* Contraindications to the use of tafalgin and\u002For morphine in accordance with the approved Summary of Product Characteristics (hypersensitivity to tafalgin, morphine, other opioids, or any excipients).\n* Pregnancy or lactation.\n* Acute or prolonged chronic intoxication with drugs or substances depressing the central nervous system (alcohol, barbiturates, opioid drugs, benzodiazepines).\n* Use of monoamine oxidase inhibitors (MAOIs) or less than 14 days since their discontinuation.\n* Liver cirrhosis, Child-Pugh class C.\n* Acute renal failure requiring renal replacement therapy.\n* Unresected malignant neoplasm.\n* Mesenteric thrombosis or another severe abdominal pain syndrome of unclear etiology at the time of inclusion.\n* Simultaneous participation in another clinical study.\n* Marked CNS depression due to any cause, except for acute poisoning.\n* COPD stage III and\u002For bronchial asthma in the exacerbation phase.\n* Any clinically significant condition, disease, or circumstance in the medical history that, in the opinion of the investigator, precludes participation in the study.\n* Psychiatric, physical, or other conditions preventing adequate assessment of the patient's behavior or proper compliance with the study protocol.\n* Postoperative hemodynamic instability requiring high-dose inotropic and\u002For vasopressor support (epinephrine \\> 0.1 μg\u002Fkg\u002Fmin, dopamine \\> 10 μg\u002Fkg\u002Fmin, norepinephrine \\> 0.2 μg\u002Fkg\u002Fmin) and\u002For mechanical circulatory support.\n* Refusal to participate in the study.","75 Years",{"count":124,"type":20},100,[23],"The goal of this clinical trial is to study postoperative analgesia in patients undergoing CABG. And learn if tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) treats pain not inferiory then morphine. The main questions it aims to answer are:\n\nDoes tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) lower the VAS score same way as a morphine? What medical problems do participants have when taking tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid)?\n\nParticipants will:\n\nGroup (1)- subcutaneous single dose of morphine 10 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nExprimental group (2)- subcutaneous single dose of tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) - 0.4 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nEfficacy was assessed using the VAS scale decreassion. Hemodynamic parameters and arterial blood gases were also assessed.",[128,129,26],"CAD - Coronary Artery Disease","CABG",[129,131,132,133,134],"CAD","Morphine","Tafalgin","VAS","2026-02-28",{"date":137,"type":35},"2026-03-05",{"date":139,"type":35},"2025-12-01",{"date":141,"type":20},"2026-03-15",{"name":143,"class":144},"Primorsky Regional General Hospital #1","OTHER_GOV",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":153,"minAge":154,"maxAge":17,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":43},"100607698","posthectomy-in-pediatric-elective-surgery--a-comparison-of-perioperative-analgesia-using-echo-guided-penile-block-and-pudendal-block-with-neurostimulation-technique-100607698","NCT07191938","Posthectomy in Pediatric Elective Surgery : a Comparison of Perioperative Analgesia Using Echo-guided Penile Block and Pudendal Block With neurostimuLation Technique","Comparison of Echo-guided Penile Block and Pudendal Block Under Neurostimulation for Perioperative Analgesia of Posthectomy in Pediatric Surgery: a Prospective, Randomized Study at Caen University Hospital","PinEAPPLE","Inclusion Criteria:\n\n* All children aged over 3 months or 60 weeks post-conceptional age scheduled for outpatient posthectomy surgery\n\nExclusion Criteria:\n\n* Recent airway infection.\n* Contraindication to locoregional anesthesia: infection and\u002For loss of substance at the puncture site, congenital or acquired coagulopathy, product allergy.\n* Contraindication to outpatient treatment: age \\\u003C 12 weeks for healthy children or 60 weeks corrected age for premature babies, unbalanced pre-existing pathology (respiratory), ability to understand and comply with instructions (pre-operative fasting, taking painkillers at home and resumption of feeding), inability to ensure the presence of 2 adults including 1 parent on the return journey by car for children \\\u003C 10 years old, easy access to care close to home.\n* Emergency surgery.\n* Coupled surgery (posthectomy + other surgery).\n* Parents' refusal to participate in the study","MALE","12 Weeks",{"count":156,"type":20},240,[23],"Context : Posthectomy is a surgical procedure that concerns around 30% of the male population, mainly in pediatrics. As this procedure is mainly performed on an outpatient basis, the implementation of an enhanced rehabilitation protocol after surgery in pediatrics helps to reduce the incidence of postoperative pain, notably by providing multimodal analgesia, including locoregional anesthesia. Current recommendations from pediatric locoregional anesthesia societies favor penile block and the use of ultrasound in pediatric anesthesia to reduce anesthetic set-up time and the volume of local anesthetic, but also to increase the duration of sensory block and the success rate. However, several studies have shown the inferiority of penile block in anatomical landmarks compared with pudendal block under neurostimulation. As a result, pediatric anesthesiologists at Caen University Hospital prefer to use pudendal blocks under neurostimulation for posthectomy surgery. To date, no study has compared penile block under ultrasound with pudendal block under neurostimulation for postoperative analgesia after posthectomy surgery. On the other hand, a study of postoperative analgesia in hypospadias surgery showed a clear superiority of penile block under ultrasound over pudendal block in terms of both immediate postoperative pain and duration of postoperative analgesia. It therefore seems pertinent to compare these two techniques in posthectomy surgery.\n\nObjective: We propose a prospective, open-label, non-inferiority study with the primary objective of comparing the efficacy of echo-guided penile block versus pudendal block in neurostimulation for posthectomy surgery.\n\nMethods: This randomized, single-center study will include 240 patients divided into two groups. The experimental group will receive optimized medical and surgical management, with a penile block under ultrasound, while the control group will receive a pudendal block under neurostimulation. The planned duration of the study is 3 years.\n\nHypothesis tested: We hypothesize that ultrasound-guided penile block is non-inferior to neurostimulated pudendal block for postoperative analgesia in scheduled posthectomy surgery. The secondary objectives are to evaluate the time taken to perform the block, the volume of local anesthetic used, the need for sufentanil reinjection intraoperatively, the quantitative evaluation of analgesia using the EVENDOL score, the consumption of nalbuphine in the post anesthesia care unit, the occurrence of postoperative vomiting, and the length of stay in the post anesthesia care unit. The rate of complications related to the performance of locoregional anesthesia is also observed.",[160,26,161,162],"Postoperative Care","Posthectomy","Postoperative Analgesia",[164,165,166,167],"Neurostimulation guided pudendal block","US guided penile block","Security","Efficiency","2025-09-22",{"date":170,"type":35},"2025-09-25",{"date":172,"type":20},"2025-09",{"date":174,"type":20},"2028-12",{"name":176,"class":42},"University Hospital, Caen",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":43},"100605757","study-comparing-atomizerd-midazolam--fentanyl-and-dexmedomidine-for-procedural-sedation-in-adult-and-pediatric-patient-2-to-60-years-old-100605757","NCT07166666","Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old)","Inclusion Criteria:\n\n* inclusion criteria:\n\n  1. Patients aged 2 to 60 years.\n  2. Patients undergoing EM procedures requiring sedation.\n\nExclusion criteria:\n\n1. Patients with contraindications to any of the sedation agents being studied.\n2. Patients with a history of adverse reactions or allergies to the study medications.\n3. Drug interactions: Patients taking certain medications that may interact adversely with the study medications.\n4. Drug Abuser\n5. Pregnancy and breastfeeding\n6. Patients with significant cardiovascular or respiratory compromise.\n7. Patients with nasal disorder (nasal trauma, epistaxis)\n8. Patients unable to provide informed consent or those with cognitive impairment.\n9. Patients who are \\\u003C 2 year of age or \\> 60 year of age.\n10. Patient underwent procedure sedation for imaging","2 Years","60 Years",{"count":186,"type":20},128,[23],"To evaluate the depth of sedation, as well as onset, and recovery times, satisfaction of sedation , adverse events associated with Atomized Midazolam \\& Fentanyl and Dexmedetomidine during procedural sedation in a diverse population spanning from 2 to 60 years old at these three prominent Omani healthcare facilities.",[190,26],"Sedation","2025-09-08",{"date":193,"type":35},"2025-09-10",{"date":195,"type":20},"2025-09-01",{"date":197,"type":20},"2026-10-01",{"name":199,"class":144},"Oman Medical Speciality Board"]